PHM Protech Home Medical Corp

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company focused on
rolling-up annuity-based healthcare service companies in the US and Canada,
today provided highlights of its FYQ1 2014 earnings call held by Chairman
Michael Dalsin and Director Roger Greene. It also announced it has appointed
Andrew Folmer to the position of Chief Financial Officer.


PHM is rolling-up a large and fragmented market of small, profitable businesses
providing healthcare products and services to chronically ill patients. PHM
plans to acquire these businesses and then offer additional, high margin
services to its entire patient base, thereby increasing revenue per patient and
achieving organic post acquisition growth.


To listen to the full earnings call please go to the link provided:

http://cc.readytalk.com/play?id=de6217

FYQ1 2014 Earnings Call Highlights



--  120% increase in revenue from the quarter a year ago. 
--  110% increase in EPS as a result of the HHC acquisition.(1)  
--  91% increase in net profit not including transaction costs and non-
    recurring costs from the quarter a year ago.(2) 
--  An increase of $5.5 million in net assets from the quarter a year ago. 
--  $8.5 million in cash at the end of FYQ1 2014, as compared to $450,000 a
    year ago 
--  $2.6 million in Accounts Receivable at the end of FYQ1 2014, as compared
    to $700,000 a year ago 
--  Two 65%+ gross margin cross selling service lines being offered to
    patients - blood thinner home monitoring and complex COPD treatment. 
--  Pipeline of 15 acquisition candidates moving toward Letters of Intent.



Andrew Folmer Appointed Chief Financial Officer

Mr. Folmer is a seasoned financial executive and leader. He has 30 years of
experience in finance, including previous work as a CFO, of which 15 years of
experience was in the healthcare industry. He is a CPA with audit and accounting
experience with major accounting firms. In the private sector, he has helped
build companies in the pharmacy and pharmaceutical businesses. Mr. Folmer served
as an executive of a startup that grew and sold to a Fortune 50 company for
approximately $100 million. He has also managed day-to-day functions in
Treasury, Operations, Sales and Marketing, Human Resources and Information
Technology. Mr. Folmer holds a BS degree in Accounting from Elizabethtown
College, where he is a member of the Baseball and Tennis Hall of Fame.


"With the recent developments in PHM, we have been able to attract a talented
and seasoned Chief Financial Officer, who will be a key player in managing our
growth and integration of acquired companies." added Mr. Dalsin. "He has
extensive experience in finance and operations, which he can use as a basis for
not only controlling costs, but also shaping the Company for future growth."


"PHM continues to strengthen its accretive roll up strategy" said Michael
Dalsin, Chairman of PHM. "We have seen a quarter with 91% EPS growth as a result
of one acquisition. I expect the acquisitions made in January will have a
positive impact on EPS this upcoming quarter. PHM is a profitable company with a
balance sheet of over $8 million in cash and a pipeline of over a dozen
qualified companies to potentially acquire."


About PHM

PHM is currently a positive cash flow and profitable company that serves
patients with heart disease and other chronic health conditions, and will act as
a platform for acquisitions. PHM is focused on a highly fragmented and
developing market of small privately-held companies servicing chronically ill
patients with multiple disease states caused mainly by age and obesity. Because
of the new and highly fragmented nature of the market, PHM is actively working
to identify and evaluate profitable, annuity-based companies to acquire their
patient databases and technical expertise at favorable prices. PHM's post
acquisition organic growth strategy is to increase annual revenue per patient by
offering multiple services to the same patient, consolidating the patient's
services and making life easier for the patient. The expected result is growing
EPS with each acquisition and growing revenue and profits from the cross selling
efforts.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.  




(1) EPS and Net Profit does not include IFRS Fair Value of options, warrants
expense, transaction cost, and non-recurring costs. EPS growth was          
calculated using the following information:                                 
                                                                            
                 Pre HHC Close Shares                  Post HHC Close Shares
-------------------------------------  -------------------------------------
                           65,027,355                             67,799,208
                                                                            
     Net Profit Excluding Acquisition       Net Profit Including Acquisition
----------------------------------------------------------------------------
                             $122,178                               $267,171
                                                                            
            EPS Excluding Acquisition                         EPS Post Close
-------------------------------------  -------------------------------------
                              0.00188                                0.00394
                                                                            
(2) Net Profit does not include IFRS Fair Value of options, warrants        
expense, transaction cost, and non-recurring costs.                         



Forward-Looking Statements 

Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, difficulty integrating
newly acquired businesses, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected. This press release refers non-GAAP and non-IFRS financial
measures that do not have standardized meaning prescribed by GAAP or IFRS. PHM's
presentation of these financial measures may not be comparable to similarly
titled measures used by other companies. These financial measures are intended
to provide additional information to investors concerning PHM's performance.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring
Sam Steinkamp
Corporate Affairs
949-556-4524

Patient Home Monitoring Corp. (TSXV:PHM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Patient Home Monitoring Corp. (TSXV:PHM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024